Pharmacokinetics and safety evaluation of intravenously administered Pseudomonas phage PA_LZ7 in a mouse model

Phage therapy is gaining traction as an alternative to antibiotics due to the rise of multi-drug-resistant (MDR) bacteria. This study assessed the pharmacokinetics and safety of PA_LZ7, a phage targeting MDR , in mice. After intravenous administration, the phage showed an exponential decay in plasma...

Full description

Saved in:
Bibliographic Details
Published in:Microbiology spectrum 2024-01, Vol.12 (1), p.e0188223-e0188223
Main Authors: Wang, Si-Yun, Tan, Xin, Liu, Zi-Qiang, Ma, Hui, Liu, Tian-Bin, Yang, Yong-Qing, Ying, Yong, Gao, Ru-Yue, Zhang, Dai-Zhou, Ma, Ying-Fei, Chen, Kai, Lin, Lin, Jiang, Zhi-Huan, Yu, Jia-Lin
Format: Article
Language:English
Subjects:
Animals
Anti-Bacterial Agents - pharmacology
Anti-Bacterial Agents - therapeutic use
antibiotic resistance
Bacteriophages
Mice
phage therapy
pharmacokinetics
Pseudomonas aeruginosa
Pseudomonas Infections - microbiology
Pseudomonas Infections - therapy
Pseudomonas Phages - genetics
Research Article
safety
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Phage therapy is gaining traction as an alternative to antibiotics due to the rise of multi-drug-resistant (MDR) bacteria. This study assessed the pharmacokinetics and safety of PA_LZ7, a phage targeting MDR , in mice. After intravenous administration, the phage showed an exponential decay in plasma and its concentration dropped significantly within 24 h for all dosage groups. Although there was a temporary increase in certain plasma cytokines and spleen weight at higher dosages, no significant toxicity was observed. Therefore, PA_LZ7 shows potential as an effective and safe candidate for future phage therapy against MDR infections.
ISSN:2165-0497
2165-0497
DOI:10.1128/spectrum.01882-23